免疫抑制剂细胞内浓度测定的研究进展

邵琨; 陈冰; 周佩军

doi:10.3969/j.issn.1674-7445.2021.04.018

免疫抑制剂细胞内浓度测定的研究进展

doi: 10.3969/j.issn.1674-7445.2021.04.018

200025 上海交通大学医学院附属瑞金医院泌尿外科移植病区（邵琨、周佩军），药剂科（陈冰）

基金项目:

国家自然科学基金 81973387

详细信息

作者简介:
邵琨，男，1979年生，博士，主治医师，研究方向为免疫抑制剂药效评价，Email：shaokunrj@163.com

通讯作者:
周佩军，男，1968年生，博士，主任医师，研究方向为移植免疫学，Email：peijunzhou@yahoo.com

中图分类号: R617, R969
计量
- 文章访问数: 821
- HTML全文浏览量: 249
- PDF下载量: 108
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-23
- 网络出版日期: 2021-07-13
- 刊出日期: 2021-07-15

Research progress on determination of intracellular concentration of immunosuppressant

Transplantation Ward of Urology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

More Information

Corresponding author: Zhou Peijun, Email: peijunzhou@yahoo.com

摘要

摘要: 细胞外浓度测定作为目前器官移植临床免疫抑制剂治疗药物监测（TDM）的主要手段，与免疫抑制剂药效之间的相关性不理想。随着液相质谱技术的广泛应用，免疫抑制剂细胞内浓度检测技术逐渐成熟。由于细胞内浓度测定可直接检测靶细胞内的药物暴露水平，理论上能更好地反映免疫抑制剂的药效。本文总结了免疫抑制剂细胞内浓度测定的历史与现状，着重介绍免疫抑制剂细胞内浓度的测定方法及其与药效的相关性。免疫抑制剂细胞内浓度测定具有较好的临床应用价值，值得推广。
- 器官移植 /
- 免疫抑制剂 /
- 治疗药物监测 /
- 药代动力学 /
- 药效学 /
- 高效液相色谱法 /
- 液相色谱-串联质谱法 /
- 外周血单个核细胞 /
- 哺乳动物雷帕霉素靶蛋白
Abstract: Currently, extracellular concentration measurement is the major approach of therapeutic drug monitoring (TDM) of clinical immunosuppressant in organ transplantation. Its correlation with the efficacy of immunosuppressant remains elusive. With widespread application of liquid chromatography, the detection technology of intracellular concentration of immunosuppressant is gradually mature. Theoretically, it may more accurately reflect the efficacy of immunosuppressant due to that the level of drug exposure in target cells can be directly measured. In this article, the history and present situation of the determination of intracellular concentration of immunosuppressant were summarized, and the association between the determination methods of intracellular concentration of immunosuppressant and drug efficacy was emphatically analyzed. Detection of intracellular concentration of immunosuppressant possesses better application value in clinical practice, which is worthy of promotion in clinical settings.
- Organ transplantation /
- Immunosuppressant /
- Therapeutic drug monitoring /
- Pharmacokinetics /
- Pharmacodynamics /
- High performance liquid chromatography /
- Liquid chromatography-tandem mass spectrometry /
- Peripheral blood mononuclear cell /
- Mammalian target of rapamycin

HTML全文

下载: 全尺寸图片幻灯片

参考文献(36)

[1]	OPTN/SRTR 2018 annual data report: introduction[J]. Am J Transplant, 2020, 20 (Suppl s1): 11-19. DOI: 10.1111/ajt.15671.
[2]	LOUPY A, LEFAUCHEUR C. Antibody-mediated rejection of solid-organ allografts[J]. N Engl J Med, 2018, 379(12): 1150-1160. DOI: 10.1056/NEJMra1802677.
[3]	SEN A, CALLISEN H, LIBRICZ S, et al. Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal[J]. Crit Care Clin, 2019, 35(1): 169-186. DOI: 10.1016/j.ccc.2018.08.011.
[4]	Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9 (Suppl 3): S1-S155. DOI: 10.1111/j.1600-6143.2009.02834.x.
[5]	COSSART AR, ISBEL NM, SCUDERI C, et al. Pharmacokinetic and pharmacodynamic considerations in relation to calcineurin usage in elderly kidney transplant recipients[J]. Front Pharmacol, 2021, 12: 635165. DOI: 10.3389/fphar.2021.635165.
[6]	SIKMA MA, HUNAULT CC, HUITEMA ADR, et al. Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation[J]. Clin Pharmacokinet, 2020, 59(4): 403-408. DOI: 10.1007/s40262-019-00846-1.
[7]	FONTOVA P, COLOM H, RIGO-BONNIN R, et al. Influence of the circadian timing system on tacrolimus pharmacokinetics and pharmacodynamics after kidney transplantation[J]. Front Pharmacol, 2021, 12: 636048. DOI: 10.3389/fphar.2021.636048.
[8]	TRON C, WOILLARD JB, HOUSSEL-DEBRY P, et al. Pharmacogenetic-whole blood and intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients[J]. PLoS One, 2020, 15(3): e0230195. DOI: 10.1371/journal.pone.0230195.
[9]	SALLUSTIO BC, NOLL BD, HU R, et al. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients[J]. Br J Clin Pharmacol, 2021, DOI: 10.1111/bcp.14806[Epub ahead of print].
[10]	CAPRON A, LERUT J, VERBAANDERT C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection[J]. Ther Drug Monit, 2007, 29(3): 340-348. DOI: 10.1097/FTD.0b013e31805c73f1.
[11]	MD DOM ZI, NOLL BD, COLLER JK, et al. Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2014, 945/946: 171-177. DOI: 10.1016/j.jchromb.2013.11.056.
[12]	ZAHIR H, NAND RA, BROWN KF, et al. Validation of methods to study the distribution and protein binding of tacrolimus in human blood[J]. J Pharmacol Toxicol Methods, 2001, 46(1): 27-35. DOI: 10.1016/s1056-8719(02)00158-2.
[13]	CAPRON A, LERUT J, LATINNE D, et al. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study[J]. Transpl Int, 2012, 25(1): 41-47. DOI: 10.1111/j.1432-2277.2011.01365.x.
[14]	KLAASEN RA, BERGAN S, BREMER S, et al. Longitudinal study of tacrolimus in lymphocytes during the first year after kidney transplantation[J]. Ther Drug Monit, 2018, 40(5): 558-566. DOI: 10.1097/FTD.0000000000000539.
[15]	HAN SS, YANG SH, KIM MC, et al. Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function[J]. PLoS One, 2016, 11(4): e0153491. DOI: 10.1371/journal.pone.0153491.
[16]	IN 'T VELD AE, GRIEVINK HW, SAGHARI M, et al. Immunomonitoring of tacrolimus in healthy volunteers: the first step from PK- to PD-based therapeutic drug monitoring?[J]. Int J Mol Sci, 2019, 20(19): 4710. DOI: 10.3390/ijms20194710.
[17]	LEPAGE JM, LELONG-BOULOUARD V, LECOUF A, et al. Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest. a prospective study on 20 renal transplant recipients[J]. Transplant Proc, 2007, 39(10): 3109-3110. DOI: 10.1016/j.transproceed.2007.03.103.
[18]	ANSERMOT N, FATHI M, VEUTHEY JL, et al. Quantification of cyclosporine A in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry using a column-switching approach[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 857(1): 92-99. DOI: 10.1016/j.jchromb.2007.07.001.
[19]	ANSERMOT N, REBSAMEN M, CHABERT J, et al. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers[J]. Drug Metab Lett, 2008, 2(2): 76-82. DOI: 10.2174/187231208784040951.
[20]	ABDELHALIM MS, KENAWY AS, DEMELLAWY HHE, et al. The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients[J]. Kidney Res Clin Pract, 2020, 39(4): 479-486. DOI: 10.23876/j.krcp.20.059.
[21]	NGUYEN THI MT, CAPRON A, MOURAD M, et al. Mycophenolic acid quantification in human peripheral blood mononuclear cells using liquid chromatography-tandem mass spectrometry[J]. Clin Biochem, 2013, 46(18): 1909-1911. DOI: 10.1016/j.clinbiochem.2013.09.009.
[22]	THI MT, MOURAD M, CAPRON A, et al. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients[J]. Clin Biochem, 2015, 48(6): 401-405. DOI: 10.1016/j.clinbiochem.2014.12.005.
[23]	CHEN B, LU JQ, SHAO K, et al. Establishment of a liquid chromatography-tandem mass spectrometry method for the determination of immunosuppressant levels in the peripheral blood mononuclear cells of Chinese renal transplant recipients[J]. Ther Drug Monit, 2020, 42(5): 686-694. DOI: 10.1097/FTD.0000000000000765.
[24]	ROULLET-RENOLEAU F, LEMAITRE F, ANTIGNAC M, et al. Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry[J]. J Pharm Biomed Anal, 2012, 66: 278-281. DOI: 10.1016/j.jpba.2012.03.042.
[25]	ROBERTSEN I, VETHE NT, MIDTVEDT K, et al. Closer to the site of action: everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations[J]. Ther Drug Monit, 2015, 37(5): 675-680. DOI: 10.1097/FTD.0000000000000185.
[26]	ROBERTSEN I, DEBORD J, ÅSBERG A, et al. A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators[J]. Clin Pharmacokinet, 2018, 57(11): 1459-1469. DOI: 10.1007/s40262-018-0646-5.
[27]	ROBERTSEN I, FALCK P, ANDREASSEN AK, et al. Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients[J]. Transplant Res, 2013, 2(1): 5. DOI: 10.1186/2047-1440-2-5.
[28]	ROMANO P, DA LUZ FERNANDES M, DE ALMEIDA REZENDE EBNER P, et al. UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4⁺ and B CD19⁺ lymphocytes[J]. J Pharm Biomed Anal, 2018, 152: 306-314. DOI: 10.1016/j.jpba.2018.01.002.
[29]	ALGHANEM SS, SOLIMAN MM, ALIBRAHIM AA, et al. Monitoring tacrolimus trough concentrations during the first year after kidney transplantation: a national retrospective cohort study[J]. Front Pharmacol, 2020, 11: 566638. DOI: 10.3389/fphar.2020.566638.
[30]	BRUNET M, VAN GELDER T, ÅSBERG A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307. DOI: 10.1097/FTD.0000000000000640.
[31]	FRANCKE MI, HESSELINK DA, LI Y, et al. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients[J]. Br J Clin Pharmacol, 2021, 87(4): 1918-1929. DOI: 10.1111/bcp.14585.
[32]	YILDIRIM E, ŞAHIN G, KALTUŞ Z, et al. Effect of CYP3A5 and ABCB1 gene polymorphisms on tacrolimus blood concentration in renal transplant recipients[J]. Clin Lab, 2019, 65(11). DOI: 10.7754/Clin.Lab.2019.190343.
[33]	SU L, YIN L, YANG J, et al. Correlation between gene polymorphism and blood concentration of calcineurin inhibitors in renal transplant recipients: an overview of systematic reviews[J]. Medicine (Baltimore), 2019, 98(26): e16113. DOI: 10.1097/MD.0000000000016113.
[34]	SHAO S, HU L, HAN Z, et al. The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: a Meta-analysis[J]. Transl Androl Urol, 2020, 9(2): 673-683. DOI: 10.21037/tau.2020.03.42.
[35]	LEMAITRE F, VETHE NT, D'AVOLIO A, et al. Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel[J]. Ther Drug Monit, 2020, 42(5): 665-670. DOI: 10.1097/FTD.0000000000000780.
[36]	METZ DK, HOLFORD N, KAUSMAN JY, et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention[J]. Transplantation, 2019, 103(10): 2012-2030. DOI: 10.1097/TP.0000000000002762.